| Title |
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, January 2013
|
| DOI | 10.1186/2050-6511-14-1 |
| Pubmed ID | |
| Authors |
Suzanne Dunne, Bill Shannon, Colum Dunne, Walter Cullen |
| Abstract |
Generic medicines are those where patent protection has expired, and which may be produced by manufacturers other than the innovator company. Use of generic medicines has been increasing in recent years, primarily as a cost saving measure in healthcare provision. Generic medicines are typically 20 to 90% cheaper than originator equivalents. Our objective is to provide a high-level description of what generic medicines are and how they differ, at a regulatory and legislative level, from originator medicines. We describe the current and historical regulation of medicines in the world's two main pharmaceutical markets, in addition to the similarities, as well as the differences, between generics and their originator equivalents including the reasons for the cost differences seen between originator and generic medicines. Ireland is currently poised to introduce generic substitution and reference pricing. This article refers to this situation as an exemplar of a national system on the cusp of significant health policy change, and specifically details Ireland's history with usage of generic medicines and how the proposed changes could affect healthcare provision. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 3 | 23% |
| United Kingdom | 1 | 8% |
| Ecuador | 1 | 8% |
| Spain | 1 | 8% |
| Canada | 1 | 8% |
| Unknown | 6 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 69% |
| Scientists | 2 | 15% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 434 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 2 | <1% |
| Colombia | 1 | <1% |
| Netherlands | 1 | <1% |
| Germany | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 427 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 82 | 19% |
| Student > Bachelor | 75 | 17% |
| Researcher | 33 | 8% |
| Student > Ph. D. Student | 32 | 7% |
| Student > Postgraduate | 26 | 6% |
| Other | 63 | 15% |
| Unknown | 123 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 96 | 22% |
| Medicine and Dentistry | 70 | 16% |
| Chemistry | 27 | 6% |
| Agricultural and Biological Sciences | 22 | 5% |
| Biochemistry, Genetics and Molecular Biology | 16 | 4% |
| Other | 67 | 15% |
| Unknown | 136 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 August 2022.
All research outputs
#1,301,984
of 25,010,497 outputs
Outputs from BMC Pharmacology and Toxicology
#19
of 475 outputs
Outputs of similar age
#11,298
of 293,517 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#2
of 14 outputs
Altmetric has tracked 25,010,497 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 475 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 293,517 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.